PHI Group Engages Research Team from Auburn University for Study of Organic Medicinal Plants
September 28 2017 - 8:30AM
InvestorsHub NewsWire
PHI Group Engages Research Team from Auburn University for Study
of Organic Medicinal Plants
Research Study to Indicate Market Segments Related to Supply and
Demand for Medicinal Plants Globally to Enable Company to Move
Production to Fast Growing Markets
New York, NY -- September 28, 2017 -- InvestorsHub
NewsWire -- PHI Group, Inc., (OTCQB:
PHIL), a company focused on mergers and acquisitions and
investments in natural resources, energy, agriculture and special
situations, announced today has commissioned a team from Auburn
University to produce research documents regarding global markets
and demand for organically grown medicinal plants. The study will
enable PHI Group to move to market segments, which will provide the
greatest return on investment (ROI).
Conventional vs Plant Based Pharmaceutical Products
Because of a growing interest and improved technology for
extracting beneficial products from medicinal plants, the
consumption and production of such compounds has increased
significantly in the last two decades. Considering that, it takes
an average of 12 years and in excess of $2.5 billion dollars to
bring conventional drugs to the market, the move to plant extracts
is well underway. The conventional drug market is expected to grow
at a CAGR of only 5.1 percent between 2013 and 2020.
Contrast this with the medicinal plant market, which is expected
to see a CAGR of 117.9 percent growth rate between 2015 and 2020.
The cost, time and safety of bringing plant-based pharmaceuticals
to market are far less of a concern as well.
Plant based drugs are far less expensive and safer because of
the avoidance of the chemical synthesis process. Plant based
pharmaceutical products are extracted from their source and
processed which renders these products in the form of active
complexes which preserves the efficacy of the original source
plant. The result is fewer or no side effects and a process that is
far less time consuming to get to the market.
Market Segment Focus for Maximum ROI
The market information and trends for this expanding market is
still limited and separated into categories of use. Therefore, the
purpose of this research is to determine the market segments
related to supply and demand of medicinal and aromatic plants in
the world, and then focus more specifically on major production and
consumption markets. Four topics of focus will be on the
production, medicinal applications, and market analysis of
turmeric, saffron, bitter melon, and some major potential medicinal
and aromatic plants. The remaining focus is on trends and solutions
of switching from conventional farming to organic farming of these
crops to meet the future food and medicinal consumption. This
research will be carried out by performing statistical and
econometric analyses on the data collected from field trip visits,
UN Comtrade, FAQ, International Organization of Scientific Research
(IOSR), the American Botanical Council, the statistics of the U.S.,
India, EU, and other Asian countries, ICIS, country reports, and
technical documents.
This research will be especially useful with regard to PHI
Groups relationship with Tho Xuan Duong
JSC, a Vietnamese company recognized by Guinness World Records that has four centuries of
history in Vietnamese traditional medicine and herbs. The
information garnered through the research will aid both companies
in broadening their reach globally in the medicinal plant-based
pharmaceutical market.
Henry Fahman, CEO of PHI Group, said, We are delighted to work
with Auburn University to focus on the production,
medicinal applications, and market analysis of turmeric, saffron,
bitter melon, and some major potential medicinal and aromatic
plants in connection with our subsidiary Abundant Farms, Inc.s
organic farming program. We believe this will help us prioritize
our execution strategy and maximize returns on investment.
On another note, Company plans to close the acquisition of the
majority interest in the 400-acre mining claims before the end of
this month and will provide an update to our shareholders next
week.
About PHI Group
PHI Group (www.phiglobal.com) primarily focuses on mergers
and acquisitions and invests in select industries and special
situations that may substantially enhance shareholder value. PHI
Group also provides M&A and consulting services through its
wholly owned subsidiary, PHI Capital Holdings, Inc. (www.phicapitalholdings.com)
Safe Harbor
This news release contains forward-looking statements that are
subject to certain risks and uncertainties that may cause actual
results to differ materially from those projected on the basis of
such forward-looking statements pursuant to the safe-harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Press Contact:
Henry Fahman
+1-702-475-5430
henry@phiglobal.com
PHI (PK) (USOTC:PHIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
PHI (PK) (USOTC:PHIL)
Historical Stock Chart
From Sep 2023 to Sep 2024